Results open the door to therapies based on chronobiology, the branch of biology that studies how living organisms structure their physiological processes in time.

Pairing a drug that targets the PRDM9 gene with a cholesterol-lowering agent shrank brain tumors and improved survival in mice.

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...